Extrait

This was an extension study for the study FE200486 CS12 (NCT00819156). Each participant was to be treated until he was discontinued or withdrawn from the study, or a marketing authorization for degarelix had been obtained. The study was terminated when all ongoing participants had been treated for at least 5 years (including one year in the main study).

Critère d'inclusion

• Prostate cancer

Pays

• Belgium
• Germany
• Hungary
• Netherlands
• Romania
• Russian Federation
• South Africa

Liens

• nct
• ictrp